Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Banking Awards
    • Banking Innovation Awards
    • Digital Banking Awards
    • Finance Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    • Financial Awards
    • Private Banking Awards
    • Private Banking Innovation Awards
    • Retail Banking Awards
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Finance
    3. >Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports
    Finance

    Novo and Hims Resolve Dispute, Will Sell Obesity Drugs Together, Bloomberg News Reports

    Published by Global Banking & Finance Review®

    Posted on March 7, 2026

    2 min read

    Last updated: April 1, 2026

    Add as preferred source on Google
    Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Global Banking & Finance Awards 2026 — Now Open for Entries
    Tags:FinanceBankinghealthcarePharmaPartnerships

    Quick Summary

    Novo Nordisk and Hims & Hers have resolved their recent dispute and will jointly sell obesity drugs via Hims’s platform, ending a legal confrontation that began in June 2025 over compounded knock‑off versions of Wegovy.

    Global Banking & Finance Awards 2026 — Call for Entries

    Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports

    Novo Nordisk and Hims & Hers Health End Dispute and Form Partnership

    Background of the Dispute

    March 6 (Reuters) - Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.

    Market Reaction

    Hims shares surged 39% in after-hours trading after the report.

    Legal and Regulatory Issues

    The report comes nearly a month after Novo sued Hims over patent infringement following the U.S. telehealth firm's launch, and then cancellation, of a $49 copy of Novo's obesity pill.

    The U.S. Food and Drug Administration had also threatened action against Hims.

    Details of the New Partnership

    Announcement Timeline

    Novo and Hims plan to announce a new partnership as soon as Monday, the report said, citing a person familiar with the matter.

    Previous Agreements and Marketing Concerns

    Last year, Novo ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims over the company's marketing tactics and continued sales of Wegovy copies.

    Statements from Both Companies

    A Novo spokesperson said in an e-mailed statement the company is "always in conversation with companies that can help improve patient access to FDA-approved medicines".

    Hims did not immediately respond to a request for comment.

    Reporting Credits

    (Reporting by Carlos Méndez in Mexico City, additional reporting by Mihika Sharma in Bengaluru; Editing by Himani Sarkar)

    References

    • Novo Nordisk ends Wegovy deal with Hims & Hers
    • Hims & Hers launches Wegovy knockoff pill, Novo Nordisk vows to sue

    Table of Contents

    • Novo Nordisk and Hims & Hers Health End Dispute and Form Partnership
    • Background of the Dispute

    Key Takeaways

    • •The renewed collaboration follows a dramatic breakup in June 2025 when Novo ended the partnership over Hims’s alleged mass sale of unauthorized compounded Wegovy versions, which Novo called deceptive and unsafe (cnbc.com).
    • •In early 2026, Hims launched a lower‑cost, unapproved Wegovy pill, prompting Novo Nordisk to vow legal and regulatory action and the FDA to signal crackdown on such copycat obesity drugs (apnews.com).

    Frequently Asked Questions about Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports

    1What companies resolved their dispute over weight-loss drugs?

    Novo Nordisk and Hims & Hers Health settled their legal dispute over selling weight-loss drugs.

    2What is the outcome of the Novo and Hims legal battle?

    Novo Nordisk and Hims plan to announce a partnership to sell obesity drugs together.

  • Market Reaction
  • Legal and Regulatory Issues
  • Details of the New Partnership
  • Announcement Timeline
  • Previous Agreements and Marketing Concerns
  • Statements from Both Companies
  • Reporting Credits
  • •The new agreement will allow Wegovy and related obesity treatments to be sold on the Hims & Hers platform again—likely under stricter compliance with FDA-approved formulations and marketing practices.
    • 3Which weight-loss drug will be available on the Hims platform?

    Wegovy, made by Novo Nordisk, will be available on the Hims & Hers Health platform.

    4When will the Novo and Hims partnership be announced?

    The partnership is expected to be announced as soon as Monday, according to sources.

    5Who reported the Novo and Hims partnership news?

    Bloomberg News reported the planned partnership between Novo Nordisk and Hims & Hers Health.

    More from Finance

    Explore more articles in the Finance category

    Image for Coffee companies launch satellite-based program to track deforestation
    Coffee Companies Launch Satellite-Based Program to Track Deforestation
    Image for BP lockout at Indiana refinery stretches into second month as union talks stall
    Bp Lockout at Indiana Refinery Stretches Into Second Month as Union Talks Stall
    Image for UK financial sector prepared for Mythos and others, says BoE co-chaired group
    UK Financial Sector Prepared for Mythos and Others, Says BoE Co-Chaired Group
    Image for Blockchain billionaire Sun takes Trump family’s crypto firm to court
    Blockchain Billionaire Sun Takes Trump Family’s Crypto Firm to Court
    Image for MFS founder faces $1.8 billion lawsuit from creditors, Bloomberg News reports
    Mfs Founder Faces $1.8 Billion Lawsuit From Creditors, Bloomberg News Reports
    Image for Explainer-How Deutsche Telecom and T-Mobile US could pull off the world's biggest M&A deal
    Explainer-How Deutsche Telecom and T-Mobile US Could Pull Off the World's Biggest M&A Deal
    Image for EU rethinks opposition to Arctic oil and gas drilling, FT reports
    EU Rethinks Opposition to Arctic Oil and Gas Drilling, Ft Reports
    Image for Microsoft to integrate Anthropic's Mythos into its security development program
    Microsoft to Integrate Anthropic's Mythos Into Its Security Development Program
    Image for UK pension investor Nest to oppose BP Chair's re-election
    UK Pension Investor Nest to Oppose Bp Chair's Re-Election
    Image for Factbox-New UBS rules: what are they and how will they impact Swiss bank?
    Factbox-New UBS Rules: What Are They and How Will They Impact Swiss Bank?
    Image for RTL wins unconditional EU antitrust approval for Sky Deutschland acquisition
    Rtl Wins Unconditional EU Antitrust Approval for Sky Deutschland Acquisition
    Image for Revolut aims to secure French and US licences this year, Western Europe CEO says
    Revolut Aims to Secure French and US Licences This Year, Western Europe CEO Says
    View All Finance Posts
    Previous Finance PostIndonesia to File Suspension of Concessions Against EU on Palm Oil Dispute in WTO
    Next Finance PostUK Discloses Four Maintenance Facilities Operating in Ukraine